Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when? / Thomas, Peter E.; Vedel-Krogh, Signe; Nordestgaard, Børge G.
I: Current Opinion in Cardiology, Bind 39, Nr. 1, 2024, s. 39-48.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Measuring lipoprotein(a) for cardiovascular disease prevention - in whom and when?
AU - Thomas, Peter E.
AU - Vedel-Krogh, Signe
AU - Nordestgaard, Børge G.
N1 - Publisher Copyright: © 2023 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2024
Y1 - 2024
N2 - Purpose of review The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity. Recent findings Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025. Summary Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
AB - Purpose of review The aim of this study is to summarize major cardiovascular guideline recommendations on lipoprotein(a) and highlighting recent findings that emphasize how measuring lipoprotein(a) once in all adults is meaningful regardless of age, sex, comorbidities, or ethnicity. Recent findings Many international guidelines now recommend once in a lifetime measurement of lipoprotein(a) in all adult individuals to facilitate accurate risk prediction. Lipoprotein(a)-lowering therapy to reduce cardiovascular disease is on the horizon, with results from the first phase 3 trial expected in 2025. Summary Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease and aortic valve stenosis and measuring lipoprotein(a) once in all individuals regardless of age, sex, comorbidities, or ethnicity is meaningful to aid in risk stratification.
KW - aortic valve stenosis
KW - atherosclerotic cardiovascular disease
KW - lipoprotein(a)
KW - primary prevention
KW - secondary prevention
U2 - 10.1097/HCO.0000000000001104
DO - 10.1097/HCO.0000000000001104
M3 - Review
C2 - 38078600
AN - SCOPUS:85179643556
VL - 39
SP - 39
EP - 48
JO - Current Opinion in Cardiology
JF - Current Opinion in Cardiology
SN - 0268-4705
IS - 1
ER -
ID: 377939811